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ABSTRACT
The Nuclear Receptor (NR) superfamily of transcription factors comprises 48 
members, several of which have been implicated in breast cancer. Most important is 
estrogen receptor-α (ERα), which is a key therapeutic target. ERα action is facilitated by 
co-operativity with other NR and there is evidence that ERα function may be recapitulated 
by other NRs in ERα-negative breast cancer. In order to examine the inter-relationships 
between nuclear receptors, and to obtain evidence for previously unsuspected roles for 
any NRs, we undertook quantitative RT-PCR and bioinformatics analysis to examine their 
expression in breast cancer. While most NRs were expressed, bioinformatic analyses 
differentiated tumours into distinct prognostic groups that were validated by analyzing 
public microarray data sets. Although ERα and progesterone receptor were dominant 
in distinguishing prognostic groups, other NR strengthened these groups. Clustering 
analysis identified several family members with potential importance in breast cancer. 
Specifically, RORγ is identified as being co-expressed with ERα, whilst several NRs are 
preferentially expressed in ERα-negative disease, with TLX expression being prognostic 
in this subtype. Functional studies demonstrated the importance of TLX in regulating 
growth and invasion in ERα-negative breast cancer cells.
INTRODUCTION
Breast cancer is the most common cancer 
diagnosed in women, making up 23% of all cancers 
in women, with 1.38 million new cases worldwide 
annually and is responsible for 460,000 deaths [1]. The 
hormone estrogen is a key proliferative driver in breast 
cancer and acts by binding to estrogen receptor-α (ERα), 
resulting in its activation. Therefore, breast cancer 
patients are stratified on the basis of tumour expression 
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of ERα. Inhibition of ERα activity using the antagonist 
tamoxifen, or drugs that inhibit estrogen biosynthesis 
by blocking the activity of aromatase, a key enzyme in 
estrogen biosynthesis (e.g. anastrozole, letrozole) [2], 
provide important strategies for the management of ERα-
positive breast cancer and significantly reduce recurrence 
and breast cancer mortality.
Despite the benefits of endocrine agents for many 
patients, a large proportion of patients with ERα-positive 
breast cancer progress on anti-estrogen or aromatase inhibitor 
therapies, or relapse following initial response [3, 4]. 
Moreover, current hormonal agents are ineffective for a fifth 
of breast cancers that do not express ERα. These problems 
highlight the need for improvements in the understanding of 
ERα-positive breast cancer, to develop additional markers 
that will identify those patients who will respond to hormone 
therapies, for developing new therapies for ERα-positive 
patients who do not respond to current endocrine therapies 
and for identifying new agents to treat patients with ERα-
negative disease.
Nuclear receptors (NR) are typically activated upon 
binding to small molecules, including steroid hormones, 
retinoids, lipids and xenobiotics and play critical roles in 
growth, development, tissue homeostasis and metabolism 
[5]. Consequently, deregulation of NR action is important 
in many diseases, including cancer. Regulation of NR 
activity by small molecule ligands has facilitated the 
development of drugs that mimic the function of cognate 
ligands (agonists) or act as inhibitors (antagonists), a 
process that is further facilitated by the availability of 
ligand binding domain crystal structures for most NRs. 
Examples of antagonists as cancer therapeutics include 
inhibitors of estrogen (tamoxifen, fulvestrant), androgen 
(flutamide, bicalutamide, MDV3100) and progesterone 
(mifepristone, onapristone, lonaprisan) receptors. 
Therapeutic synthetic agonists and antagonists, many 
being approved for clinical use, have also been developed 
for many other NRs, including the glucocorticoid (GR; 
dexamethasone), vitamin D3 (VDR), retinoid, and 
peroxisome proliferator activated (PPARs) receptors [6]. 
Therefore, identification of NRs with functional roles 
in breast cancer development and progression has the 
potential for rapid progression to the clinic.
The progesterone receptor (PGR) is well-established 
as an ERα-regulated gene Indeed, clinical practice includes 
the routine immunohistochemical determination of PGR; 
PGR expression is almost always observed only in ERα 
positive breast cancer [7] and its presence is a presumed 
marker of ERα functionality. Furthermore, increased risk 
of breast cancer has been reported for post-menopausal 
women with hormone replacement therapies (HRT) that 
include synthetic progestins [8]. Hence, anti-progestins 
have been tested in the metastatic setting [9] and clinical 
trials using the anti-progestin mifepristone in the early 
stage breast cancer setting are underway (ClinicalTrials.
gov: NCT01138553).
Importantly, recent studies provide new evidence 
to show that some NRs act co-operatively with ERα in 
breast cancer cells, often through co-regulation of gene 
expression. Thus, retinoic acid receptor-α (RARα), whose 
expression is estrogen-regulated in breast cancer, localizes 
to ERα binding sites to modulate the expression of ERα 
target genes [10, 11], establishing crosstalk between 
estrogen and retinoid signalling that is important for the 
growth of ERα-positive breast cancer cells. LRH-1 is 
another ERα-regulated NR, which stimulates proliferation 
and promotes motility and invasion of breast cancer cells 
and regulates the expression of estrogen-responsive genes 
in ERα+ breast cancer cells, acting in a co-operative 
manner with ERα [12].
The androgen receptor (AR), another NR whose 
expression is strongly associated with ERα expression 
in breast cancer [13], inhibits expression of estrogen 
responsive genes in ERα-positive breast cancer 
cells. Remarkably, in a small subset of ERα-negative 
“molecular apocrine” breast cancer [14], AR activates, 
rather than inhibits, the expression of many ERα target 
genes through its recruitment to sites that are normally 
bound by ERα in luminal MCF7 cells [15], suggesting 
that in ERα-negative breast cancer some NRs can, at least 
in part, take the role of ERα.
It appears, therefore, that NRs co-expressed with 
ERα play important roles in the regulation of gene 
expression by ERα and consequently in breast cancer, 
whilst other NRs have been implicated in ERα-negative 
breast cancer [16, 17]. These findings prompted us to 
determine the expression profiles of all NRs in different 
breast cancer subtypes using quantitative RT-PCR (qRT-
PCR). Our analysis confirms the co-expression of several 
NRs with ERα, but also identifies other NRs whose 
expression is strongly associated with ERα, in particular 
a previously unreported relationship with retinoic acid 
receptor-related orphan receptor-γ (RORγ). Further, 
we show that expression of the Tailless homolog TLX 
(NR2E1) is negatively associated with ERα, TLX being 
expressed in ERα-negative breast cancer and confirm this 
relationship through analysis of published microarray data 
sets. Functional studies demonstrate that TLX regulates 
breast cancer cell growth and invasion, identifying TLX 
as a new therapeutic target in breast cancer.
RESULTS
Quantitative RT-PCR profiling demonstrates 
expression of the majority of nuclear receptors 
in breast cancer
To determine the NR expression profiles in 
tumours representative of different breast cancer 
subtypes, total RNA was prepared from 128 breast 
tumours from the Tayside Tissue Bank, for which 
clinical and histopathological details were available, 
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as well as long term clinical follow-up. For qRT-PCR, 
we designed a Taqman TLDA card, to include assays 
for 47 NR, together with GAPDH as a control. This 
arrangement excluded an assay for COUP-TF1 (NR2F1), 
since the only real-time assays available for COUP-TF1 
at the time also detect COUP-TF2 (NR2F2). Most NRs 
were expressed in this patient cohort, with ERα, RARα, 
EAR2, COUP-TF2 and RXRβ being the most highly 
expressed NRs (Figure 1). Interestingly, COUP-TF2 and 
EAR2 expression levels were high in ERα-positive, as 
well as ERα-negative tumours (Table 1; Supplementary 
Figures 1–2). Although more highly expressed in ERα-
positive breast cancer, high-level RARα expression 
was also evident in ERα-negative tumours. Expression 
of CAR, SHP and FXR was undetectable in the great 
majority of cases.
Consensus cluster analysis to differentiate breast 
cancers in different groups
Unsupervised hierarchical consensus clustering 
[18] was used to discern molecular subclasses of breast 
tumours with similar NR expression profiles. Consensus 
cluster analysis provided evidence for separation of the 
tumours into two, three or four clusters (Supplementary 
Figure 3), with two clusters exhibiting the most 
stable configuration (Figure 2A). For the two clusters, 
Kaplan-Meier (KM) survival plots showed that patients 
segregating to cluster 2 have a significantly better 
prognosis, compared with patients in cluster 1 (HR = 2.55 
(1.06–6.12), p = 0.029) (Figure 2B). Determination of 
the association of the two clusters with clinical features 
showed that cluster 2 samples were likely to be of lower 
Figure 1: Relative expression of Nuclear Receptors in RNA prepared from breast tumours. The normalized mRNA expression 
of each NR is shown for RNAs prepared from 128 breast tumours. Each dot represents one patient sample. Real-time RT-PCR was performed 
for all NR, excepting COUP-TF1. The NRs are ordered using the NR superfamily nomenclature: 0B, DAX-like receptors; 1A, Thyroid 
Hormone Receptors; 1B, Retinoic acid receptors; 1C, Peroxisome proliferator-activated receptors; 1D, Rev-Erb receptors; 1F, RAR-related 
orphan receptors; 1H, Liver X receptor-like receptors; 1I, Vitamin D receptor-like receptors; 2A, Hepatocyte nuclear factor-4 receptors; 2B, 
Retinoid X receptors; 2C, Testicular receptors; 2E, Tailless-like receptors; 2F, COUP-TF-like receptors; 3A, Estrogen receptors; 3B, Estrogen-
related receptors; 3C, 3-Ketosteroid receptors; 4A, Nerve growth factor IB-like receptors; 5A, Fushi tarazu F1-like receptors; 6A, Germ cell 
nuclear factor receptors.
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Table 1: Expression levels of nuclear receptors in 128 breast cancers
High expression Moderate expression (15 > to > 5) Low/Absent expression (≤ 5)
All Tumors
ERα 17.49 (13.55 – 
19.36)
PPARδ 14.92 (14.24 – 
15.45)
RORα 12.93 (12.19 – 13.57) SF-1 4.11 (0.73 – 7.28)
EAR2 17.34 (16.77 – 
17.93)
TR4 14.77 (14.00 – 
15.42)
NOR1 12.26 (11.33 – 13.37) HNF4α 3.59 (−0.10 – 6.65)
RARα 16.61 (15.58 – 
18.06)
TRα 14.69 (13.82 – 
15.52)
PPARγ 11.91 (11.22 – 13.06) TLX 2.38 (0.02 – 6.21)
COUP-
TF2
15.77 (14.85 – 
16.62)
Nurr77 14.59 (13.49 – 
15.57)
PPARα 11.75 (11.20 – 12.34) DAX1 1.38 (−0.58 – 5.24)
RXRα 15.65 (15.01 – 
16.27)
GR 14.51 (13.67 – 
15.24)
ERRγ 11.30 (9.83 – 12.58) SHP 0.34 (−0.77 – 3.42)
LXRß 15.62 (15.10 – 
16.21)
Rev-ErbAß 14.48 (13.96 – 
15.19)
MR 11.26 (10.13 – 12.6) FXR −0.07 (−1.06 – 1.33)
AR 15.62 (14.19 – 
16.36)
VDR 14.46 (13.99 – 
15.00)
PGR 10.74 (8.10 – 15.15) CAR −0.11 (−1.07 – 0.78)
RXRß 15.46 (14.01 – 
17.00)
Rev-ErbAα 14.35 (13.52 – 
15.39)
LRH-1 10.70 (9.41 – 11.63)
RARγ 14.15 (13.34 – 
14.90)
GCNF 10.31 (9.33 – 11.39)
RORγ 14.01 (12.84 – 
14.95)
RORß 9.25 (8.22 – 10.75)
ERRα 13.62 (12.33 – 
14.28)
PNR 8.33 (6.30 – 10.05)
TRß 13.26 (12.11 – 
14.30)
PXR 8.03 (6.24 – 10.13)
TR2 13.15 (12.53 – 
13.81)
ERß 7.93 (6.66 – 8.94)
NURR1 13.14 (11.91 – 
14.00)
ERRß 7.31 (6.28 – 8.71)
LXRα 13.05 (12.06 – 
14.09)
RXRγ 7.20 (6.01 – 8.24)
RARß 13.00 (11.71 – 
15.30)
HNF4γ 5.01 (1.39 – 7.77)
ERα-positive
ERα 18.7 (17.24 – 
19.95)
PPARδ 14.93 (14.27 – 
15.48)
RORα 13.02 (12.50 – 13.71) HNF4γ 4.97 (1.43 – 8.16)
EAR2 17.52 (17.03 – 
18.03)
TRα 14.90 (14.29 – 
15.74)
RARß 12.91 (11.54 – 15.21) HNF4α 4.11 (0.24 – 6.84)
RARα 17.24 (15.91 – 
18.84)
TR4 14.86 (14.06 – 
15.48)
NOR1 12.40 (11.51 – 13.49) SF-1 3.57 (0.55 – 6.65)
LXRß 15.95 (15.29 – 
16.43)
Nurr77 14.78 (13.97 – 
16.27)
PPARγ 12.10 (11.40 – 13.10) TLX 0.86 (−0.51 – 3.56)
(Continued )
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High expression Moderate expression (15 > to > 5) Low/Absent expression (≤ 5)
COUP-
TF2
15.93 (15.11 – 
16.78)
Rev-ErbAß 14.72 (14.06 – 
15.42)
PPARα 11.52 (11.07 – 12.07) DAX1 0.69 (−0.67 – 4.61)
AR 15.88 (15.15 – 
16.56)
GR 14.60 (13.98 – 
15.33)
ESRRG 11.31 (10.25 – 12.38) SHP 0.56 (−0.67 – 3.8)
RXRα 15.87 (15.37 – 
16.35)
VDR 14.58 (14.08 – 
15.00)
MR 11.26 (10.17 – 12.65) FXR 0.1 (−0.75 – 1.31)
RXRß 15.37 (14.10 – 
17.44)
Rev-ErbAα 14.51 (13.90 – 
15.63)
LRH-1 11.01 (9.83 – 11.74) CAR 0.1 (−0.86 – 0.79)
RARγ 14.46 (13.79 – 
15.13)
GCNF 10.40 (9.39 – 11.67)
RORγ 14.35 (13.45 – 
15.08)
RORß 9.75 (8.81 – 11.46)
PGR 13.98 (10.34 – 
15.81)
PNR 9.38 (7.87 – 10.60)
TRß 13.61 (12.45 – 
14.42)
ERß 7.90 (6.55 – 8.87)
ERα 13.49 (12.33 – 
14.27)
PXR 7.88 (6.30 – 10.19)
NURR1 13.34 (12.40 – 
14.21)
ERRß 7.86 (6.81 – 8.97)
TR2 13.27 (12.82 – 
14.02)
RXRγ 7.60 (6.19 – 8.66)
LXRα 13.10 (12.12 – 
14.07)
ERα-negative
EAR2 16.89 (16.15 – 
17.46)
PPARδ 14.91 (14.2 – 
15.34)
ERα 12.14 (11.18 – 13.55) DAX1 4.54 (−0.08 – 6.06)
RARα 15.54 (13.79 – 
16.64)
TR4 14.59 (13.91 – 
14.92)
NURR1 12.12 (11.12 – 13.36) HNF4α 2.36 (−0.43 – 5.82)
RXRß 15.49 (13.89 – 
16.51)
VDR 14.29 (13.41 – 
14.93)
NOR1 11.89 (11.27 – 13.14) SHP −0.18 (−1.35 – 2.63)
COUP-
TF2
15.37 (14.22 – 
15.96)
GR 14.23 (13.28 – 
14.83)
PPARG 11.50 (10.94 – 12.96) FXR −0.27 (−1.73 – 1.26)
LXRß 15.29 (14.72 – 
15.73)
Rev-ErbAß 14.15 (13.53 – 
14.56)
MR 11.25 (10.05 – 12.46) CAR −0.27 (−1.67 – 0.64)
RXRα 14.99 (14.37 – 
15.53)
TRα 14.06 (13.08 – 
15.15)
ERRγ 10.87 (9.12 – 13.03)
Nurr77 13.88 (13.16 – 
14.65)
LRH-1 9.94 (8.80 – 10.96)
Rev-ErbAα 13.81 (13.26 – 
14.63)
GCNF 9.72 (8.76 – 10.85)
ERRα 13.70 (12.92 – 
14.41)
PXR 8.49 (6.21 – 9.84)
(Continued )
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tumour grade (p = 0.001), although tumour grade trended 
towards, but did not reach significant association with 
survival in this patient cohort (Supplementary Figure 4). 
Moreover, there was an association between the clusters 
and immunohistochemically (IHC) determined ERα (p = 
4.1E-14) and PGR (p = 1.4E-12) status (Figure 2A), 
with the better prognosis group (cluster 2) being 
enriched in ERα and PGR positive tumours. There was 
no relationship between the clusters and HER2 status 
(p = 1.0) and although patients with PGR positive disease 
had better survival than PGR negative patients, this also 
did not reach significance (p = 0.113) in our patient cohort 
(Supplementary Figure 5). Patients with IHC determined 
ERα-positivity had a better prognosis than the ERα-
negative patients (HR = 0.41 (0.18 – 0.91); p = 0.024).
We have seen that ERα and PGR mRNA levels were 
not associated with patient outcome in univariate analysis, 
regardless of the expression level cut-offs used, suggesting 
that other NRs are important contributors to the survival 
differences observed for the two clusters, at least when 
examining expression at the mRNA level. To investigate 
this, we used unsupervised consensus clustering analysis 
with different partitions, k = 2 to k = 6, in order to cluster 
NR gene expression (Supplementary Figure 5). The 
empirical cumulative distribution function indicated an 
approximate best stability for k = 3, indicating that the 
optimal number of robust NR clusters in this data set is 
three (Figure 2C). Gene Cluster B, which contained ERα, 
also contained the known ERα-regulated genes PGR, 
RARα and LRH-1. This cluster also contained AR and 
PNR, both previously shown to be co-expressed with ERα 
in breast cancer [13, 19], as well as ERRγ. High-level 
ERRγ expression has previously been associated with ERα 
and PGR-positivity, although the statistical significance of 
the previously reported associations was weak (p = 0.054 
and p = 0.045, respectively) [20]. Also present in the ERα 
cluster were TRß, RORß, and RORγ. The Kruskal-Wallis 
test, used to determine association between ERα, PGR 
and HER2 IHC status and PGR (p = 1.10E-14), AR (p = 
8.86E-07), RARα (p = 7.07E-06), LRH-1 (p = 1.44E-03), 
as well as TRß (p = 3.06E-04), RORß (p = 2.70E-03) 
and RORγ (p = 1.18E-04) mRNA expression provides 
further evidence in support of the association between 
expression of these receptors and ERα (Supplementary 
Figures 1–2). The Mann-Whitney test further confirmed 
association between the expression of these NRs and ERα 
(Table 2). It should be noted that despite the co-clustering 
of ERRγ with ERα, the association for ERRγ did not reach 
significance (p = 0.603).
To obtain further evidence for the association 
between ERα expression and expression of these NRs, 
we analysed a number of gene expression microarray 
data sets. The data sets used were chosen on the basis 
of patient number and/or availability of follow-up 
information on outcome and included the METABRIC 
series of nearly 2, 000 cases [21], the TCGA series of 
about 500 cases [22] and the 300+ cases in GSE20685 
[23]. As expected, there were highly statistically 
High expression Moderate expression (15 > to > 5) Low/Absent expression (≤ 5)
AR 13.68 (10.70 – 
15.70)
RORß 8.26 (7.08 – 9.37)
RARγ 13.58 (13.02 – 
14.10)
PGR 8.06 (7.05 – 9.69)
RARß 13.47 (12.31 – 
15.41)
ERß 8.01 (6.78 – 9.17)
LXRα 13.03 (11.99 – 
14.24)
RXRγ 6.40 (5.76 – 7.21)
RORγ 12.98 (12.32 – 
14.20)
TLX 6.29 (3.80 – 8.40)
TR2 12.61 (11.83 – 
13.47)
ERRß 6.14 (5.14 – 7.35)
TRß 12.55 (11.10 – 
13.40)
PNR 5.41 (3.12 – 7.34)
RORα 12.50 (11.78 – 
13.33)
SF-1 5.03 (2.32 – 7.48)
PPARα 12.26 (11.72 – 
12.75)
HNF4γ 5.03 (1.15 – 7.28)
Expression levels (ΔCt values) relative to undetectable expression (Ct > 35). Median expression is shown, together with the 
25 and 75 percentile range.
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significant positive associations between ERα IHC 
status and ERα mRNA levels, as well as with PGR, AR 
and RARα (Table 2). Of the other NRs co-clustering 
with ERα in our qRT-PCR samples, evidence for co-
expression of ERα with TRß, ERRγ, RORß or LRH-1 
was less equivocal, not reaching statistical significance 
in one out of the three microarray datasets. However, 
association between ERα and PNR expression was 
evident, as previously reported [19]. The association 
between ERα and RORγ, which has not previously 
been described, was confirmed in the microarray 
series. Expression of RORγ in breast cancer cells was 
determined by expression analysis in breast cancer cell 
lines (Figure 6A), which also showed association of 
RORγ with ERα expression (Mann-Whitney; p = 0.014).
Identification of nuclear receptors for 
distinguishing patient groups
We next determined if the consensus clustering 
signature generated from the qRT-PCR analysis that 
separates our patient cohort into good and poor prognosis 
groups, could be extended to the microarray data sets. To 
do this, we performed Random Forest (RF) classification 
[24] with the tumour cluster classification obtained from 
consensus clustering as categorical factors to generate a 
model using z-score transformed qRT-PCR data set. As the 
number of trees may affect classification error, RF analysis 
was carried out for 5000, 10000, 20000 and 50000 trees, 
with the best error stability being exhibited for 50,000 
trees (Figure 3A). We then validated this classifier with 
Figure 2: Identification of two main breast cancer subtypes based on NR gene expression. A. Unsupervised hierarchical 
consensus clustering segregates tumours into two clusters based on qRT-PCR for NR expression. Shown is the ERα, PGR and HER2 
IHC status for each tumour, positive tumours being depicted as pink (ERα), blue (PGR) and red (HER2) bars. Statistical significance was 
established using Fisher’s exact test. B. Kaplan-Meier plot shows patient survival for the patients in the two clusters. Crosses show censored 
samples. C. Heatmap representation of hierarchical consensus cluster analysis of nuclear receptor mRNA expression. Tumours are grouped 
according to the two clusters identified from consensus clustering. Median centred NR expression in patient samples is shown in a heat map 
following the arrangement of NRs and tumour samples according to the clusters identified in the consensus cluster analysis.
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two data sets, GSE20685 [23], which included patient 
survival information for 327 samples and the METABRIC 
samples (n = 1,959). In both cases, cluster 2 was 
significantly associated with better prognosis (HR = 2.32 
(1.36–3.95), p = 0.002 and HR = 1.86 (1.51–12.30), p = 
5.1 × 10−9, respectively) (Figure 3B). This indicates that 
the NR expression signature derived from our qRT-PCR 
analysis separates breast tumours into two prognostically 
different groups, although given the significantly greater 
number of ERα and PGR positive tumours in cluster 2, it 
is likely that ERα and PGR are important determinants 
in this expression signature. Indeed, plotting variable 
importance showed that ERα and PGR are especially 
important, but also highlighted several other NRs as 
important classifiers of clusters 1 and 2 (Figure 3C). 
To further confirm the important variables, RF was run 
re-iteratively for NRs, removing the bottom most NR 
(assigned the least variable importance score), one at a 
time. This showed that the top 8 NR, namely ERα, PGR, 
DAX1, TLX, PNR, RARγ, RARα and Rev-erbAß provide 
the lowest error rate (Figure 3D), highlighting these NRs 
as the most important variables for differentiating the two 
tumour clusters.
We next used Pairwise Pearson correlation 
coefficient (PCC) to further define relationships between 
NRs. PCC confirmed associations between groups of NRs, 
particularly for NRs in the ERα cluster, as well as a close 
relationship for the NR4A receptors, NURR1, NUR77 
and NOR1 (Figure 4). Of particular note is the fact that 
expression of TLX, identified as an important variable in 
the Random Forest analysis, was negatively associated 
with ERα mRNA expression (PCC = −0.37, p-value = 
1.97E-05). TLX expression was also negatively associated 
with clinical ERα (IHC) status (p = 5.5E-07; Table 2). 
However, evidence for association of DAX1 expression 
with ERα status (p = 2.9E-02) and ERα mRNA (PCC = 
−0.10, p = NS) was seen to be weak. Nor did examination 
of the microarray data indicate an association between 
ERα and DAX1. By contrast, the negative association 
between ERα and TLX was confirmed in the METABRIC 
(p = 5.5E-07) and GSE20685 (p = 1.3E-02) datasets. As 
ERα is a positive prognostic factor in breast cancer, TLX 
expression might be expected to be associated with poor 
outcome. Survival analyses showed that TLX expression 
in breast cancer is indeed associated with poor survival 
in the GSE20685 (HR = 1.77 (1.12 – 2.79), p = 0.0137) 
Table 2: Association between ERα and Select NR expression (Mann-Whitney)
Positive Association with ERα
qRT-PCR METABRIC* TCGA# GSE20685§
Sample No. Analysed n = 128 n = 1,980 n = 485 n = 327
ERα 3.6E-18 2.4E-188 2.8E-47 9.6E-48
PGR 4.6E-11 9.6E-102 1.7E-29 6.4E-34
PNR 1.9E-10 4.9E-110 1.8E-34 1.5E-11
AR 7.6E-60 7.8E-28 8.0E-16
RORß 1.9E-06 1.7E-06 1.2E-02 3.4E-01
RARα 1.3E-06 3.0E-88 1.2E-24 1.3E-07
TRß 9.2E-05 8.1E-01 1.7E-08 1.4E-08
RORγ 2.6E-04 2.3E-44 1.5E-15 7.3E-08
LRH-1 1.9E-03 4.1E-03 5.8E-04 2.9E-01
ERRγ 6.0E-01 1.8E-05 4.4E-02 3.1E-01
Negative Association with ERα
qRT-PCR METABRIC TCGA GSE20685
TLX 5.5E-07 2.7E-10 1.6E-15 1.3E-02
PPARα 3.3E-04 1.1E-34 4.3E-28 1.4E-12
DAX1 2.9E-02 1.7E-02 4.0E-03 6.7E-01
*21 samples were excluded because of lack of follow-up information
#51 samples were removed from analysis due to incomplete information or sample duplication
§ERα status is based on cut-offs for ERα positivity determined from the microarray expression profiling data by the authors 
[44]. For the other data sets IHC determined ERα status has been applied for the analysis.
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Figure 3: Random Forest (RF) analysis to generate a classification model for risk groups identifies NR of highest 
importance in generating breast cancer clusters. A. Shown is an error rate plot for 50,000 trees generated. The curves represent the 
error rates for cluster 1 (red), cluster 2 (green) and the “Out-of-Bag (OOB) error rate (black). B. Kaplan-Meier plot shows association of the 
NR expression signature identified by RF analysis with disease specific survival for the GSE20685 (26) and METABRIC (28) microarray 
data sets. C. Dot chart of NR importance as measured by RF analysis. D. Shown is OOB error for 50,000 RF trees. The red dots represent 
the OOB errors for the number of NRs using in RF, each analysis excluding the least important NR. Thus, in the case of 8 NR, which yields 
the lowest error, only the top 8 NR from part B were used for RF.
Oncotarget21694www.impactjournals.com/oncotarget
and METABRIC (HR = 1.32 (1.01 –1.71), p = 0.041) 
series (Figure 5). Our analyses also showed that TLX is 
predominantly expressed in poor prognosis, ERα-negative 
breast cancers. Intriguingly, however, in these tumours, 
high expression of TLX in the absence of ERα is related 
to better survival, as seen in ERα-negative (HR = 0.69 
(0.48 – 0.99), p = 0.048) and the PAM50 basal subtype 
(HR = 0.58 (0.37 – 0.93), p = 0.023).
TLX regulates morphology, growth and invasive 
behaviour of triple-negative breast cancer cells
Our analyses highlight a potentially significant role for 
TLX in triple-negative and/or basal subtype breast cancer. 
Only 33% of ERα and/or HER2 positive breast cancer cell 
lines expressed TLX, compared with 60% of the triple-
negative lines (Figure 6B). The role of TLX in triple-negative 
breast cancer was evaluated using MDA-MB-157 cells, 
which had the highest TLX expression in the breast cancer 
cell line panel. RNAi-mediated TLX knockdown clearly 
inhibited proliferation in MDA-MB-157 cells, an effect that 
was observed with three independent siRNAs (Figure 7A, B). 
TLX knockdown similarly inhibited the growth of another 
triple-negative cell line, MDA-MB-468, which expresses 
moderate levels of TLX. All three TLX siRNAs failed to 
affect the growth of two lines that do not express TLX (BT20, 
JIMT1), arguing against off-target effects being responsible 
for the growth effects due to these siRNAs observed in the 
TLX expressing lines.
The invasive capacity of both lines was also 
markedly reduced following TLX silencing (Figure 7C), 
accompanied by significant inhibition in expression of 
epithelial-mesenchymal cell transition (EMT) markers 
such as MMP7, MMP9, vimentin and E-cadherin 
(Figure 7D). Since EMT can be associated with stem cell 
enrichment in breast cancer cells, we investigated the role 
of TLX on characteristics associated with breast cancer 
stem cells by investigating aldehyde dehydrogenase 
1 (ALDH1) activity. TLX siRNA resulted in reduced 
expression of ALDHA1 and activity, determined using 
the Aldefluor assay (Figure 7E, F). The mammosphere 
assay provides an in vitro method for quantifying stem 
cell activity and self-renewal [25]. TLX knockdown 
resulted in a significant reduction in mammosphere 
forming efficiency in both cell lines (Figure 7G). Ectopic 
expression of TLX in MDA-MB-231 cells. In agreement 
with the siRNA results, TLX expression promoted 
growth, invasion and mammosphere formation in MDA-
MB-231 cells (Figure 8), supporting the results of the TLX 
knockdown.
Figure 4: Pairwise Pearson Correlation Coefficient (PCC) analysis identifies NRs whose expression is positively or 
negatively associated with ERα expression. A. Positive correlations (of 1 for self-comparisons) are depicted in blue, colour intensity 
reflecting the value of the correlation. The highest positive correlation value was 0.79. Negative associations are shown in red, with the 
colour intensity increasing with greater negative correlation, the greatest negative value being 0.37.
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DISCUSSION
Given the important gene regulatory roles for NRs 
in cancer and their drugability, we performed unsupervised 
hierarchical consensus clustering to analyse real-time, 
quantitative RT-PCR gene expression data for NR 
expression from 128 breast cancers. This allowed a broad 
separation of tumours into two prognostic groups, where 
univariate analysis suggested that ERα and PGR, together 
with other NRs acted to affect survival differences. 
To further investigate this, we have used unsupervised 
consensus clustering analysis to define associations 
between NR gene expression in breast cancer and have 
found evidence for three gene clusters.
NR gene cluster A comprised SHP, HNF4α and 
NR4A subfamily members. The NR4 subfamily members 
Nurr1, Nur77 and NOR1 were highly expressed in most 
samples, irrespective of tumour subtype. By contrast, SHP 
and HNF4α expression was low or absent in most tumours. 
Therefore, the co-clustering of these NRs is likely to 
be a reflection of a lack of differential expression across 
the range of tumours in our patient series. The high level 
expression of all three members of the NR4A receptors 
across the tumours is interesting, particularly in light of 
recent observations of increased expression of these NRs 
in breast cancer, compared with the normal breast [26]. 
NR4A receptors are important, albeit in a context-dependent 
manner, positive or negative regulators of cell survival and 
apoptosis [27]. Indeed, siRNA-mediated Nurr1 knockdown 
reduced growth of tumour xenografts [28], whereas Nur77 
agonists inhibit MCF-7 cell proliferation and promote 
apoptosis [29]. However, another study has demonstrated 
Figure 5: TLX expression is a marker of poor prognosis in breast cancer, but is associated with better prognosis in 
ERα-negative breast cancer. Kaplan-Meier survival plots for TLX expression in GSE20685 [23] and METABRIC [21] microarrays is 
shown for all tumours and for ERα-negative and basal subtype tumours.
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that Nur77 over-expression does not affect proliferation or 
apoptosis in a number of breast cancer cell lines; rather the 
migratory potential of breast cancer cell lines, as well as 
that of the immortalized MCF-10a cell line, was diminished 
[30]. Given the elevated expression of NR4A receptors in 
the majority of breast cancers, greater consideration of the 
function of these NRs and their potential as therapeutic 
targets and biomarkers in breast cancer is clearly warranted.
Gene cluster B contained ERα and a group of NRs 
previously associated with ERα in breast cancer, including 
PGR, AR, RARα, LRH-1, PNR, as well as TRß, RORß, and 
RORγ. We have referred to cluster B as the “ERα Cluster” 
Figure 6: mRNA Expression of RORγ and TLX in Breast Cancer Cell Lines. A. Heat map representation of NR expression 
in breast cancer cell lines is shown. The ERα, PGR and HER2 status of each cell line is also depicted. B, C. RORγ and TLX expression in 
breast cancer cell lines is shown relative to expression levels of GAPDH.
Oncotarget21697www.impactjournals.com/oncotarget
and note that a key feature of this is a functional association 
with the estrogen response, as seen for the activity for ERα, 
together with RARα, [10, 11], and more recently LRH-1, 
where we have found a functional co-operation between this 
NR and ERα through the use of common gene regulatory 
elements [12]. The association between ERα and RORγgene 
expression in breast cancer and breast cancer cell lines is 
novel and would require further characterisation.
Gene Cluster C contained NRs whose activation has 
been associated with the inhibition of breast cancer cell 
growth, including GR, RARß, RARγ, RORα, PPARγ and 
VDR [16, 17], as well as ERß, TR2 and TR4 whose role 
in breast cancer may lie, at least in part, with their action 
in reducing or inhibiting ERα activity [31–33]. These 
NRs were not differentially expressed in ERα/PGR/HER2 
subgroups, with the exception of RARγ whose expression 
appeared to be lower in HER2-positive than in HER2-
negative tumours, although statistical significance for 
association with HER2 status was not reached (p = 0.076). 
Other NRs in cluster C that have been implicated in breast 
cancer include ERRα, which is highly expressed in our 
samples. ERRα regulates breast cancer cell proliferation in 
in vitro and in vivo models and genetic deletion of ERRα 
delays tumour formation in a transgenic model of HER2-
induced mammary tumourigenesis [34]. Transcriptomic 
studies have in particular highlighted the importance of 
ERRα and metabolism in breast cancer cells [35].
An important consideration is the fact that non-
cancer components, particularly the stroma, as well as 
lymphocyte infiltration may influence NR expression 
profiles, although NR expression in stroma and/or 
lymphocyte infiltration, may be of some importance in 
breast cancer progression. For example, LRH-1 drives 
aromatase expression in cancer-associated stroma [36], 
while lymphocyte infiltration is associated with good 
prognosis [37], and response to chemotherapy [38] in 
Figure 7: Targeted knockdown of TLX inhibits the growth of ERα-negative breast cancer cell lines. MDA-MB-157 and 
MDA-MB-468 cells were transfected with a non-targeting siRNA (siControl), or with three independent siRNAs for TLX. Each experiment 
included three replicates and three independent experiments were carried out. Error bars show standard errors of the mean, asterisks 
represent p < 0.05, relative to the siControl. A. Cell number was assessed using the SRB assay 5 days following transfection. Growth 
is shown relative to the SRB values for day 0. B, D, F. Real-time RT-PCR was performed using RNA prepared from siRNA-transfected 
cells. mRNA expression was normalised to GAPDH expression. Bar charts represent mRNA levels compared to the siControl samples. 
C. Cells transfected with siRNAs were used in the transwell invasion assay. Bars represent number of invading cells. E. ALDH activity was 
determined using the Aldefluor assay. Bars show the percentage of Aldefluor-positive cells. G. Mammosphere forming efficiency (%) was 
calculated as the number of mammospheres formed in 10 days, divided by the original number of single cells seeded.
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ERα-negative disease. Two major RORγ isoforms have 
been described, with RORγt being highly expressed in 
lymphocytes. Our expression NR profiling used a real-
time assay that would detect RORγ1, as well as the 
RORγt isoform. It is therefore possible that expression of 
the RORγ expression, presents expression in infiltrating 
lymphocytes, in addition to its expression in the cancer 
cells. In mitigation, expression profiling of NRs in diverse 
mouse tissues showed that SF-1 is one of 17 NRs that are 
expressed at moderate to high levels in tissues associated 
with the immune system (spleen, thymus) [39]. The near 
absence of SF-1 expression suggests that infiltrating 
lymphocytes only make up a minor component of the 
tumour cell population in our samples. Notwithstanding, 
we note that RORγ is expressed in many breast cancer 
cell lines and its expression is greater in ERα-positive 
than In ERα-negative cell lines, a relationship that is also 
observed in the tumour RNAs, as well as in microarray 
datasets. Further exploration of the functional importance 
of RORγ in breast cancer is therefore warranted.
Our analysis has also highlighted TLX as a gene 
of interest, since it is important in differentiating the two 
tumour clusters we have defined, where it is negatively 
associated with ERα mRNA expression and is associated 
with poor survival. Interestingly, TLX is one of a small 
number of genes expressed in breast cancer that predict 
for the presence of circulating tumour cells (CTC) [40]. 
Furthermore, tumours classified as CTC-positive in that 
Figure 8: Ectopic expression of TLX promotes breast cancer cell growth, invasion and mammosphere formation. MDA-
MB-231 cells were transfected with TLX or with the vector control (pcDNA3). A. Cell number was assessed using the SRB assay 4 days 
following transfection. Growth is shown relative to the SRB values for the vector control (n = 3). B. Real-time RT-PCR was performed 
using RNA prepared from transfected MDA-MB-231 cells. mRNA expression was normalised to GAPDH expression. Bar charts represent 
mRNA levels compared to the vector control (n = 3). C. Protein lysates prepared from transfected cells were immunoblotted for TLX 
and ß-actin. D. Cells transfected with TLX were used in the transwell invasion assay. Bars represent number of invading cells (n = 3). 
E. Mammosphere forming efficiency (%) was calculated as the number of mammospheres formed in 10 days, divided by the original 
number of single cells seeded (n = 6).
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study were more likely to be ERα-negative. Low level/
absence of TLX expression in ERα-positive breast cancer 
and elevated expression in ERα-negative breast cancer 
may be due to the proposed different cellular origins of 
luminal and basal breast cancer sub-types, due to their 
origin in luminal and basal cells, respectively, or from 
different progenitor cells [41]. Interestingly, the most 
closely related NR to TLX is PNR, which promotes ERα 
expression in breast cancer cells through direct recruitment 
to the ERα gene promoter [19]. TLX and PNR both bind 
as monomers to very similar DNA motifs and given that 
TLX appears to function mainly as a transcriptional 
repressor [42], raising the intriguing possibility that TLX 
might repress ERα expression from the PNR binding site.
TLX regulates the proliferation and renewal 
potential of neural stem cells, where it acts as a 
transcriptional repressor through the recruitment of co-
repressors, histone deacetylases (HDAC) and lysine-
specific histone demethylase (LSD1) [43, 44], whilst a 
recent study defined a role for TLX in the regulation of 
neural stem cell senescence [45]. p53 is frequently lost 
in gliomas and TLX over-expression promoted glioma 
formation in p53 null mice [46]. There is, however, no 
evidence for TLX function in tissues other than the brain 
and NR profiling in a panel of mouse tissues (which 
did not include the mammary gland) showed little or 
no expression in tissues other than in the CNS [39], 
although TLX expression has been reported in cell lines 
representative of some cancer types [47].
We have found that siRNA mediated inhibition of 
TLX expression in breast cancer cell lines leads to an 
inhibition of cell growth, invasive potential and cancer 
stem cell properties, supporting the conclusion that TLX 
is important in breast cancer. In neural stem cells, TLX 
represses the expression of negative regulators of cell 
cycle progression and proliferation, including p21, p57 
and PTEN (60), as well as stimulating the Wnt/ß-catenin 
pathway through the direct activation of Wnt7a [48]. 
Our data demonstrate a functional role for TLX in breast 
cancer cells, although we did not observe de-repression 
of p21, p57 or PTEN expression (data not shown). Nor 
was expression of Wnt7A altered. This indicates that the 
action of TLX in breast cancer cells is mediated through 
target genes that are distinct from those implicated in 
neural stem cells. Other potentially relevant mechanisms 
of TLX function include the regulation of microRNAs, 
including the up-regulation of miR-9 [49], which has been 
implicated in breast cancer [50, 51]. Clearly, as a potential 
target, the mechanism by which TLX functions in ERα-
negative breast cancer requires further investigation.
In summary, quantitative, real-time RT-PCR 
analysis of breast cancers revealed that the majority 
of NRs are expressed in breast cancer. Unsupervised 
hierarchical consensus clustering separated the tumours 
into clusters with prognostic significance. As expected, 
ERα and PGR were key variables in the prognostic 
groups. These analyses NRs whose expression profiles 
are indicative of their importance in different breast 
cancer subtypes. However, our results do not preclude 
the importance of other NRs, which are widely expressed 
across breast cancer subtypes, for example COUP-
TFs, Nurr1/Nurr77/NOR1, RXRs, LXRs and PPARs. 
Indeed, a recent study mapping global binding sites for 
24 nuclear receptors in the ERα-positive MCF-7 breast 
cancer cell line [52] provides evidence for the coordinate 
binding of many NRs to target regions throughout the 
genome, as exemplified by PPARδ, which as our results 
show is widely expressed across breast cancer subtypes. 
Our clustering analysis does nevertheless identify the 
orphan nuclear receptor TLX as an important variable in 
breast cancer, which is preferentially expressed in ERα-
negative breast cancer where its importance is indicated 
by the prognostic significance of its expression and siRNA 
mediated growth inhibition and EMT. Secondly, we have 
uncovered a significant association between ERα and 
RORγ expression. Taken together, our profiling exercise 
describes two NRs whose function in breast cancer needs 
greater study.
MATERIALS AND METHODS
Human breast cancer samples
The patients presented with primary, operable breast 
cancer to the Dundee Cancer Centre between 1997 and 
2012 and provided written, informed consent for research 
use of their tissues. Use of the clinical material and data 
was approved by the Tayside Tissue Bank under delegated 
authority from the Tayside Local Research Ethics 
Committee. ERα, PGR and HER2 immunohistochemical 
staining and scoring were carried out as described [53]. 
For HER2, all cancers scoring “equivocal” (2+) by IHC, 
were subjected to HER2 FISH analysis carried out using 
the PathVysion™ HER2 DNA probe kit (Vysis, Abbott 
Laboratories, Illinois, USA), with amplification of 2 fold 
or greater considered HER2 amplified. HER2 IHC positive 
(3+) cases, as well as FISH-positive HER2 IHC 2+ cases 
were scored as HER2-positive.
Cell lines
Authenticated cell lines obtained from American 
Type Culture Collection were cultured according to 
ATCC recommendations for RNA preparation. Cell lines 
were authenticated using the short tandem repeat (STR) 
profiling service (LGC Standards, UK) immediately prior 
to initiation of studies.
RNA extraction
Frozen breast tumour tissue (50 to 100 mg) was 
homogenized using TissueLyser (Qiagen) with stainless 
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steel ball bearings (5 mm) in 0.7 ml of Lysis/Binding 
Buffer (Ambion) and total RNA was isolated according to 
the manufacturer's instructions. Removal of contaminating 
DNA from the RNA preparation was performed using 
DNA-free™ kit (Ambion/Life Technologies) following 
the manufacturer's protocol. The concentration and purity 
of total RNA was assessed using a NanoDrop™ 1000 
spectrophotometer (Nanodrop Technologies, Wilmington, 
DE, USA).
Reverse transcription
2.5 μg of total RNA was reverse converted to 
cDNA in a volume of 20 μl using RevertAid M-MuLV 
reverse transcriptase (Fermentas, York, UK), according 
to manufacturer’s protocols. The reactions were carried 
out in the GeneAMP 9700 PCR machine (Applied 
Biosystems/Life Technologies, Paisley, UK) at 42°C for 
1 hour, followed by 5 minutes at 95°C.
TaqMan low-density array (TLDA)
384-well TLDA microfluidic cards were designed 
so as to include the Taqman real-time gene expression 
assays for 47 of the 48 human nuclear receptors that are 
included in the Taqman Human Nuclear Receptor Array 
(ABI cat. No.: 4379961). The Taqman assay for COUP-
TF1 (NR2F1) was excluded from our TLDA array as 
the manufacturer has flagged this assay as amplifying 
COUP-TF2 (NR2F2), in addition to NR2F1. No other 
pre-designed Taqman assays exclusively amplifying 
COUP-TF1 were available from ABI at the time. Also 
included in our TLDA design was an assay for the 
glycerol-2-phosphate dehydrogenase (GAPDH) gene, as 
a control. The TLDA cards were purchased from Applied 
Biosystems (Life Technologies, Paisley, UK). For each 
tumour sample, cDNA was diluted 1:10 in ribonuclease-
free water. A total volume of 100 μl reaction mixture, 
containing 50 μl of diluted cDNA and 50 μl of Taqman 
universal master mix was added to a TLDA fill reservoir. 
Each TLDA card was designed to assay 8 individual 
samples. The TLDA cards were then centrifuged twice at 
1200 rpm for 2 minutes, sealed and run on an ABI 7900HT 
real time instrument (Life Technologies, Paisley, UK).
Expression analysis of TLDA data set
TLDA card data were analysed using SDS2.2/RQ 
manager (ABI/Life Technologies). The quantification 
cycle threshold was kept constant and set at 0.15 across 
samples for data comparison, following manufacturer’s 
instructions. The relative quantification to GAPDH 
expression was performed using DataAssist™ v3.0 (ABI/
Life Technologies) and results exported to Microsoft excel 
for data processing. All values in the data set were log-
2 transformed for further statistical analysis, as has been 
described [39].
Statistical analysis
Statistical analyses were performed using R 2.15.1 
software. Additional software packages (Consensus Cluster 
Plus, randomForest, corrplot, Hmisc, GMD, survival) were 
downloaded from the Comprehensive R Archive Network 
(CRAN).
Unsupervised consensus clustering was performed 
using R package ConsensusClusterPlus [18], using a median-
centered expression matrix. The procedure was carried out 
with 1000 repetitions, 80% item resampling (pItem), a 
maximum evaluated number of groups (k) of 10 and use of 
an agglomerative hierarchical clustering algorithm with a 
distance metric given by one minus the Pearson correlation.
Random forest (RF) analysis was carried out 
using R package RandomForest [24]. The tumour cluster 
classification derived from consensus clustering served as a 
categorical factor for the RandomForest algorithm to generate 
a model using z-score transformed qRT-PCR dataset. The 
number of variables (NRs), randomly selected as candidates 
at each node was set to 7 and 5, 000, 10, 000, 20, 000 or 
50, 000 trees were grown to reach tree numbers at which 
classification error reached stability. The default values were 
used for the remaining parameters throughout the analysis.
The consensus clustering heatmap was generated 
using the heatmap.3 code provided in the GMD package 
[54]. The dendrogram (clustering tree) for tumour and 
NR clustering were directly extracted from the consensus 
clustering analysis. For visualization, the expression data 
were normalized using median centred approach.
Pairwise Pearson Correlation Coefficient (PCC) 
analysis of NR in tumours was computed using Hmisc 
package. The resulting correlation coefficient and the 
matrix of p-value data were used as input to plot the 
correlation matrix graph using corrplot.
Breast cancer specific survival was estimated 
using R package survival [55] with the non-parametric 
product limit method (Kaplan-Meier). Continuous data 
were categorized into high expression or low expression, 
based on lower/upper quartile cut offs. Univariate Cox 
proportional hazards regression were used for examination 
of risk factors and given with corresponding hazard ratios 
(HR) and 95% confidence intervals. A p-value < 0.05 was 
considered as significant and all p-values were two tailed.
Gene expression microarray data
GSE20685 was downloaded from Gene Expression 
Omnibus (GEO) [23]. The TCGA breast dataset was 
downloaded from The Cancer Genome Atlas Data Portal 
[22]. The METABRIC microarray data have been reported 
previously [21].
RNA interference
BT20, JIMT1, MDA-MB-157 and MDA-MB-468 
cells were cultured in Dulbecco’s modified Eagle’s medium 
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(DMEM) containing 10% fetal calf serum (FCS). Cells were 
transfected with double-stranded RNA oligonucleotides 
using the Lipofectamine RNAiMax reverse transfection 
method (Invitrogen, UK), as described previously [12]. TLX 
siRNA #1 (s14200), #2 (s14201), #3 (s14202) and control 
siRNA (4390846) were purchased from Ambion. RNA was 
prepared 48 hours following transfection and real-time RT-
PCR was performed, as described above. Real-time assays 
for TLX (Hs01128417_m1), ALDH1A1 (Hs00946916_m1), 
MMP7 (Hs01042796_m1), MMP9 (Hs00234579_m1), 
vimentin (Hs00185584_m1), E-cadherin (CDH1, 
Hs01023894_m1) and GAPDH (Hs99999905_m1) were 
purchased from ABI. Cell growth was determined using the 
sulphorhodamine B (SRB) assay, as described previously 
[12]. The transwell cell invasion assay, mammosphere 
culture and determination of ALDH activity were carried 
out as previously described [56].
TLX transfection
MDA-MB-231 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% fetal 
calf serum (FCS). Cells were transfected with a FLAG-
tagged TLX expression plasmid [57] using Fugene HD 
(Promega, UK), as described previously [12].
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